CASI Pharmaceuticals Inc. (CASI)
(Real Time Quote from BATS)
$3.30 USD
+0.03 (0.92%)
Updated May 16, 2024 12:56 PM ET
3-Hold of 5 3
C Value F Growth NA Momentum NA VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CASI 3.30 +0.03(0.92%)
Will CASI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CASI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CASI
USANA Health Sciences (USNA) Q3 Earnings Miss Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)
CASI: What are Zacks experts saying now?
Zacks Private Portfolio Services
ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
Other News for CASI
Casi Pharma spikes as FDA clears clinical trial for blood disorder therapy
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Casi receives permission to proceed with CID-103 study from FDA
CASI Pharmaceuticals: A Buy Rating Amid Financial and Clinical Promise